Setipiprant CAS: 866460-33-5

CAS NO: 866460-33-5
Setipiprant
Chemical Name: Setipiprant
Molecular Formula: C24H19FN2O3
Formula Weight: 402.42
CAS No.: 866460-33-5
Description Review
Description

Setipiprant is a drug that was originally developed as a treatment for asthma. However, it has since gained attention as a potential treatment for hair loss due to its ability to block the action of prostaglandin D2 (PGD2).

Chemical Name:

The chemical name for Setipiprant is 1-(4-{[5-(4-cyanophenyl)-2-thiazolyl]amino}ethyl)-N,N-dimethyl-1H-pyrazole-5-carboxamide.

Molecular Formula:

The molecular formula of Setipiprant is C20H21N5O2S.

Formula Weight:

The formula weight of Setipiprant is 383.48 g/mol.

CAS No:

The CAS number of Setipiprant is 866460-33-5.

Top Ten Keywords from Google and Synonyms:

  1. Hair Loss Treatment
  2. PGD2 Blocker
  3. Alopecia Treatment
  4. Topical Solution
  5. Asthma Drug
  6. Prostaglandin Inhibitor
  7. Scalp Hair Regrowth
  8. Hair Growth Stimulant
  9. Dermatological Agent
  10. SetiPlex

Health Benefits of Setipiprant:

Setipiprant is believed to provide various health benefits due to its potential ability to block the action of PGD2. Some of the potential benefits of Setipiprant include:

  1. Hair Regrowth: Setipiprant may promote hair regrowth and prevent further hair loss in individuals with androgenetic alopecia.

  2. Reduced Inflammation: Setipiprant may reduce inflammation in the scalp by blocking the action of PGD2.

Potential Effects:

Setipiprant can produce a range of effects depending on the dosage and individual response. Some of the potential effects of Setipiprant include:

  1. Improved Hair Growth: Setipiprant may improve hair growth by blocking the action of PGD2.

  2. Reduced Inflammation: Setipiprant may reduce inflammation in the scalp by blocking the action of PGD2.

Product Mechanism:

Setipiprant works by blocking the action of PGD2, which is known to contribute to hair loss in individuals with androgenetic alopecia. By reducing inflammation and promoting hair growth, Setipiprant may provide various health benefits.

Safety:

Setipiprant can be safe when used appropriately and under medical supervision. However, it can cause adverse effects if misused or abused. Some of the potential side effects of Setipiprant include:

  1. Skin Irritation: Setipiprant may cause skin irritation or allergic reactions in some individuals.

  2. Gastrointestinal Disturbances: Setipiprant may cause gastrointestinal disturbances, such as nausea or diarrhea, in some individuals.

Dosing Information:

The appropriate dose of Setipiprant depends on several factors such as age, weight, and health status. It is essential to follow dosing instructions carefully and not exceed the recommended dose.

Conclusion:

Setipiprant is a drug that was originally developed as a treatment for asthma but has gained attention as a potential treatment for hair loss. While Setipiprant may provide some health benefits, it should only be used under medical supervision and with caution due to its potential side effects. Additionally, more research is needed to fully understand its safety and efficacy in humans

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code